Document Detail


Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors: Results of a Pilot Trial.
MedLine Citation:
PMID:  21325939     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: Octreotide is a somatostatin analog, long-acting formulations of which have been used experimentally for the treatment of patients with invasive tumors and/or residual disease after conventional therapies. The objective of this retrospective study was to evaluate the efficacy of long-acting octreotide (Sandostatin LAR) for the treatment of thymic tumors, with a primary efficacy end point of progression-free survival. METHODS: Between 1994 and 2010, 44 patients with thymic malignancies were evaluated. Twenty-seven patients underwent an OctreoScan, and 12 OctreoScan-positive patients were treated with long-acting octreotide at a dose of 20 mg, given as an intramuscular injection, every 2 weeks. RESULTS: Treatment with long-acting octreotide gave the following results: 3 cases of partial response (25%), 5 cases of stable disease (42%), and 4 cases of progressive disease (33%), with an average progression-free survival of 8 months (range, 3 to 21). Treatment compliance and tolerability were good for all evaluated patients. CONCLUSIONS: The results of this study confirm the somatostatin receptor as a valid target for the treatment of thymic malignancies. Overall, therapy with long-acting somatostatin analogs seems to be safe and effective.
Authors:
Flavia Longo; Lucilla De Filippis; Andrea Zivi; Domenico Vitolo; Ester Del Signore; Bruno Gori; Daniele Diso; Marco Anile; Federico Venuta; Tiziano De Giacomo; Camillo Furio Coloni
Related Documents :
3658289 - Results of second-look laparotomy in patients with early-stage ovarian carcinoma.
8422279 - The impact of received dose intensity on the outcome of advanced ovarian cancer.
2227579 - Gallstone ileus masquerading as recurrent carcinoma of the ovary.
2535999 - Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas.
7199819 - The changing role of "second-look" laparotomy in the management of epithelial carcinoma...
18452079 - Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related...
20009889 - The impact of complete surgical staging upon survival in early-stage ovarian clear cell...
8632529 - Radical nephrectomy for renal cell carcinoma 30 mm. or less: long-term follow results.
22424569 - Low levels of human cytomegalovirus infection in glioblastoma multiforme associates wit...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-15
Journal Detail:
Title:  American journal of clinical oncology     Volume:  -     ISSN:  1537-453X     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-2-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Departments of *Clinical Oncology †Pathology ‡Thoracic Surgery, University "La Sapienza", Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Role of Genotype in 104 Cases of Diffuse Large B-Cell Lymphoma Primary of Breast.
Next Document:  Thyroid Transcription Factor-1 in Primary CNS Tumors.